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Peripheral nerve functional recovery after nerve injury generally requires multiple growth factors by synergistic effect. How-
ever, the optical combination of multiple synergistic growth factors for axonal regeneration has been scarcely considered up to 
now. Meanwhile, the use of growth factors in promoting nerve regeneration was limited by its short biological half-life in vivo, 
its vulnerability to structure disruption or hydrolyzation, leading to loss of bioactivity. Herein, a novel polymeric nanoparticle 
delivery system composed of heparin and ε-poly-L-lysine (PL) was prepared for control release of nerve growth factor (NGF) 
and basic fibroblast growth factor (bFGF). The nanoparticles were synthesized by polyelectrolyte complexation in aqueous so-
lution at room temperature, followed by cross-linking with biological genipin. The obtained nanoparticles had a spherical 
shape, with a mean diameter of about 246 nm, and high growth factors encapsulation efficiency as well as good stability. NGF 
and bFGF were encapsulated in the nanoparticles and showed a continuous and slow release behavior in vitro. The bioactivities 
of the released growth factors were evaluated, and exhibited the synergistic effect. The controlled release of the dual synergis-
tic growth factors would improve the treatment of peripheral nerve injury to mimic the natural cellular microenvironments. 
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Peripheral nerve injury is a critical and devastating condi-
tion that is usually caused by traumatic injury and often 
results in life-long disability, for example, permanent func-
tional and sensory deficits [1]. When the long peripheral 
nerve defect cannot be repaired by end-to-end suturing, a 
nerve graft between the proximal and distal nerve stumps is 
often necessary for promoting the nerve regeneration [1,2]. 
The representative nerve graft selection is an autologous 
nerve graft self-donated from another part of the body. 
However, this recognized gold standard technique com-
pared with other treatments for peripheral nerve repair is 
limited by the inherent drawbacks, such as secondary injury 
at the donor site, tissue availability, formation of neuroma, 
and the mismatch between nerve and graft in tissue struc-
ture and size [3]. To overcome these disadvantages of au-
tologous nerve graft, various biochemical engineering of 
nerve guidance conduits based on artificial or natural mate-
rials has emerged as an alternative choice to bridge nerve 
gaps [46]. These guidance conduits have significant merits 
in peripheral nerve repair, such as no need for a second 
surgery, assistance in guiding the regenerating axons from 
the proximal to distal stumps and minimizing the infiltration 
of fibrous scar tissue [7]. At present, these nerve guidance 
conduits for the treatment of peripheral nerve injuries have 
limited functional capacity to repair short nerve defect [8]. 
However, this method often results in the deficient clinical 
results or the entire failure of nerve regeneration in the case 
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of longer nerve gap. One of the main causes of the poor 
clinical nerve regeneration is inadequate growth factors 
support in the nerve regeneration microenvironments [9]. 
Accordingly, increasing functional requirements for nerve 
conduit become necessary since they should not only serve 
as a desirable support but also a satisfactory carrier to 
achieve suitable functional recovery for long nerve defect. 
For improving the function of nerve guides, the bioactive 
strategy containing growth factors is investigated to mimic 
the natural cellular microenvironments [10,11]. 
Growth factors are naturally occurring proteins and pol-
ypeptides that could stimulate the cellular survival, prolifer-
ation and differentiation [12]. Growth factors also play an 
important role for neuronal survival and axonal regeneration 
via the binding to specific classes of tyrosine kinase recep-
tors existing on the surface of the responsive cells, which is 
a prerequisite for effective reinnervation of the injured 
nerves [1,13]. They have been widely used in tissue engi-
neering approaches for the repair of peripheral nerve inju-
ries and nerve defects. Two of the attractive factors are 
nerve growth factor (NGF) and basic fibroblast growth fac-
tor (bFGF). NGF could promote the growth, maintenance 
and survival of sensory and motor neuron, and regulate the 
synthesis of protein and metabolism of sugar and fat in the 
neuron [14]. bFGF is a representative member of the hepa-
rin-binding growth factors, and could promote the survival 
and neurite extension of neurons from the central nervous 
system in vitro, stimulating proliferation of the glial cells 
such as astrocytes, oligodendrocytes, and schwann cells 
[15,16]. Much evidence has indicated that after nerve injury 
the local presence of growth factor at the injury sites plays a 
vital and complex role in controlling the survival, prolifera-
tion, migration and differentiation of various cell types in-
volved in nerve regeneration [17]. Additionally, recent 
studies demonstrated that the optimal combination of multi-
ple growth factors elicits synergistic effect on axonal regen-
eration in vitro and in vivo [18]. It could be ascribed to that 
single factor treatment may not be optimal as nerves gener-
ally comprise different neuronal subpopulations that depend 
on different growth factors. However, the optical combina-
tion of multiple synergistic growth factors for axonal regen-
eration has been scarcely considered up to now. 
The growth factors could be generally delivered by direct 
injection or release from a carrier. When the growth factors 
were administrated by direct injection, their applications 
were limited by their short biological half-life in vivo, their 
vulnerability to structure disruption or hydrolyzation, lead-
ing to loss of bioactivity at the defect site [19]. Moreover, 
growth factors also show minimal tissue penetration which 
may result in ineffective delivery at the defect site [20]. 
Among the strategies developed to improve protein’s bioa-
vailability and absorption, the use of colloidal carriers, es-
pecially nanoparticle delivery carriers, is an emerging strat-
egy under investigation [21]. Compared with the direct ad-
ministration, the growth factors encapsulated within the 
carriers can be more efficiently used than free growth fac-
tors, and therefore, the amount of growth factors required 
can be reduced. Furthermore, nanoparticle drug delivery 
carriers, owing to their sub-cellular and sub-micron size, 
could easily penetrate into tissues and fine capollaries and 
control the dosage and delivery period of biomolecules with 
the purpose of enhancing the efficacy of the growth factors 
[22]. These drug delivery systems are developed not only to 
improve the biological utilization of growth factors by con-
trolling drug release to the target site, but also to protect 
their bioactivity from degradation by direct exposure to the 
harsh environments. Therefore, increasing interests and in-
tensive efforts have been devoted to biomedical drug deliv-
ery carriers composed of biodegradable and biocompatible 
natural polymer at the nanoscale.  
In this study, a novel polymeric nanoparticle delivery 
system composed of heparin and ε-Poly-L-lysine (PL) was 
prepared for control release of the growth factors. The hep-
arin-PL nanoparticles were synthesized by polyelectrolyte 
complexation in aqueous solution at room temperature, fol-
lowed by cross-linking with biological genipin. The nano-
particles were characterized by dynamic light scattering 
(DLS), transmission electron microscopy (TEM) and scan-
ning electron microscopy (SEM). NGF and bFGF were 
loaded in the nanoparticles with high encapsulation effi-
ciency and showed a continuous and slow release behavior 
in vitro. The bioactivities of the released growth factors 
were evaluated by the number of neurite-bearing PC12 cells. 
It is demonstrated that two growth factors could elicit the 
synergistic effect on the neurite growth of PC12 cells. 
1  Materials and methods 
1.1  Materials 
ε-Poly-L-lysine (PL, n=2535) was purchased from Zhe- 
jiang Silver Elephant Bioengineering Co., Ltd. (China). 
Heparin (Mw, 600020000) was bought from Shanghai 
Yuanye Reagent Company. Genipin was supplied by 
Shanghai Aladdin Reagent Company. Nerve growth factor 
7.0s (NGF) was purchased from EMD Millipore Corpora-
tion. Recombinant human basic fibroblast growth factor 
(bFGF) was purchased from PeproTech, Inc (Rocky Hill, 
USA). Mouse NGF enzyme-linked immunosorbent assay 
(ELISA) kit and human bFGF ELISA kit were purchased 
from Shanghai Yuanye Reagent Company, China. All other 
reagents were of analytical purity grade and used without 
further purification. 
1.2  Preparation of heparin-PL nanoparticles 
In a typical run, PL solution (1 mL of a 3 mg mL1 aqueous 
solution) was added dropwise to 2 mL of heparin aqueous 
solution (3 mg mL1) under stirring, and the mixture was 
258 Zhang LZ, et al.   Sci China Life Sci   February (2014) Vol.57 No.2 
stirred for 1 h at room temperature. Genipin (2.3 mg) was 
then added to the reaction system at room temperature and 
cross-linked for 12 h. After cross-linking, the aggregates 
were removed by passing the solution through a 0.22 μm 
filter. The nanoparticles were collected by centrifugation at 
10000 r min1 and redispersed in the predetermined volume 
of distilled water. 
1.3  Preparation of growth factors loaded nanoparticles 
Briefly, PL solution (1 mL of a 3 mg mL1 aqueous solution 
containing NGF (0.5 μg) and bFGF (0.5 μg)) was added 
dropwise to 2 mL of heparin aqueous solution (3 mg mL1) 
under stirring, and the mixture was stirred for 1 h at room 
temperature. Genipin (2.3 mg) was then added to the reac-
tion system at room temperature and cross-linked for 12 h. 
After cross-linking, the aggregates were removed by pass-
ing the solution through a 0.22 μm filter. The nanoparticles 
were collected by centrifugation at 10000 r min1 and re-
dispersed in the predetermined volume of distilled water.  
Similarly, the bFGF loaded nanoparticles or NGF loaded 
nanoparticles were prepared by adding PL solution contain-
ing 1 μg bFGF or 1 μg NGF to the heparin solution and 
cross-linked as described above. 
1.4  Characterization of nanoparticles 
Particle size of the nanoparticles we carried out using a dy-
namic light scattering instrument (Brookhaven Instruments 
Corporation, USA). Each sample of the nanoparticles was 
adjusted to a concentration of 0.05% (w/v) in filtered water 
or 0.01 mol L1 NaCl solution in the case of zeta potential 
examination. All analyses were performed in triplicate at 
25°C and the results were the average of the three runs. The 
morphology of prepared nanoparticles was examined by 
transmission electron microscopy (TEM; JEOL JEM-1010). 
10 μL of the nanoparticle suspension was placed onto a 
200-mesh carbon-coated copper grid for 2 min, and after 
air-drying the samples were observed. Scanning electron 
microscopy (SEM) observations were performed on 
HITACHI S-4800. 
1.5  Growth factor encapsulation efficiency 
The encapsulation efficiency of growth factors in the nano-
particles with different formations was determined by cen-
trifuging the nanoparticle suspension at 10000 r min1 at 
4°C for 30 min. The amount of growth factor in clear su-
pernatant was determined using the ELISA using a pre- 
established calibration curve. The encapsulation efficiency 
was calculated by the following formulas: 
Encapsulation efficiency % 
 
weight of growth factor in the nanoparticles
weight of the feeding growth factor
  
1.6  In vitro release of the growth factors loaded nano-
particles 
A suspension of the growth factors loaded nanoparticles in 
water was dialyzed against 10 mL of phosphate buffer solu-
tion (PBS, 0.01 mol L1) with different pH values at 37°C. 
After a predetermined period, 1 mL aliquots was withdrawn 
and the nanoparticles were centrifuged at 10000 r min1 at 
4°C for 30 min. The growth factor concentration in sampled 
release medium was determined by ELISA using a 
pre-established calibration curve. The measurements were 
performed in triplicate and the results were the average of 
the three times. 
1.7  In vitro cytotoxicity 
The cytotoxicity of samples were tested by using a MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) assay. Rat Schwann cell line (RSC-96) cells were 
grown in a Dulbecco’s modified Eagle’s medium (DMEM) 
with 2 mmol L1 glutamine, 100 U mL1 penicillin and 100 
µg mL1 streptomycin. The culture medium was supple-
mented with 10 % fetal bovine serum in a 5% CO2 atmos-
phere at 37°C. The cells were seeded into a 96-well plate, 
and incubated with 100 µL of culture medium containing a 
series of doses of samples at 37°C for 24 h. After incubation, 
the culture media in each well were removed and cells were 
washed three times with PBS. Then, 20 µL of MTT solu-
tions (5 mg mL1) was added to each well and cultured for 
another 4 h. The supernatant was discarded and 100 µL of 
DMSO was added to each well. The A values of plates were 
observed on a microplate reader at 570 nm (Safire, Tecan, 
Switzerland). 
1.8  NGF and bFGF bioactivity by PC12 cell bioassay 
Rat PC12 cells were grown in DMEM with 2 mmol L1 
glutamine, 100 U mL1 penicillin and 100 µg mL1 strepto-
mycin. The culture medium was contained with 10% horse 
serum and 5% fetal bovine serum in a 5% CO2 atmosphere 
at 37°C. Prior to differentiation of the PC12 cells, the well 
plate was coated with poly-L-lysine overnight. The cells 
were seeded into a 24-well plate and incubated with the 
culture medium at 37°C cultured for 7 d. The culture me-
dium consisted of DMEM medium supplemented with var-
ious samples: control group, blank nanoparticles, NGF (100 
ng mL1), NGF loaded nanoparticles (NGF, 100 ng mL1), 
bFGF (100 ng mL1), bFGF loaded nanoparticles (bFGF, 
100 ng mL1), NGF+bFGF (NGF, 100 ng mL1; bFGF, 100 
ng mL1) and NGF+bFGF loaded nanoparticles (NGF, 100 
ng mL1; bFGF, 100 ng mL1). Fresh growth factor formu-
lations were added to the media every two days.  
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1.9  Immunocytochemistry  
Cultured cells were fixed in freshly prepared 4% paraform-
aldehyde for 10 min at room temperature, and then permea-
bilized with 0.1% triton X-100/PBS for 15 min. After 
washing three times with PBS for 10 min, the cells were 
blocked with 10% BSA (blocking buffer) for 45 min at 
room temperature. Cells were incubated with mouse mono-
clonal β-tubulin III and rabbit anti-neurofilament (NF) 200 
IgG fraction of antiserum for 2 h followed by further reac-
tion with Alexa Fluor 488 donkey anti-mouse IgG and 
Alexa Fluor 594 donkey anti-rabbit IgG. Afterwards, the 
cells were stained by DAPI for 10 min. Representative flu-
orescent images were observed using a Leika fluorescence 
microscope.  
2  Results and discussion 
2.1  Preparation of heparin-PL nanoparticles 
In order to develop the effective method to deliver growth 
factors, a reaction nanoparticulate system was selected in 
aqueous solution consisting of a cationic biomacromolecule, 
PL, and an anionic biomacromolecule, heparin. Due to their 
well-established properties, such as water-solubility, bio-
degradability and high biocompatibility, PL and heparin 
were chosen as the starting material in the design of vectors 
for growth factors delivery [23,24]. Furthermore, heparin 
could have specific affinity with many growth factors and 
then has been widely utilized for growth factor delivery to 
optimize and extend the growth factor delivery kinetics, 
prevent their degradation and enhance binding to cell sur-
face receptors [25,26]. Additionally, it was previously re-
ported that heparin improves the axonal growth in the pe-
ripheral nerve injury [27]. 
The heparin-PL nanoparticles were prepared by poly-
electrolyte complexation and covalent cross-link with gen-
ipin in aqueous solution at room temperature, as schemati-
cally shown in Figure 1A. The driving force of the for-
mation of the nanoparticles can be ascribed to the complex-
ation through the intermolecular electrostatic interaction 
between the polycationic PL with the polyanionic heparin. 
Subsequently, the nanoparticles were crosslinked by bio-
logical genipin, which is superior to traditional crosslinking 
agents in terms of lower cytotoxicity and has proven to have 
neuritogenic activity and neuroprotective effects [28,29].  
2.2  Characterization of heparin-PL nanoparticles 
The mean hydrodynamic diameter of the obtained nanopar-
ticles was determined to be 246 nm in aqueous medium of 
pH 7.4 by DLS (Figure 1B), suggesting that the particles are 
well dispersed in aqueous solution. The morphology and 
structure of the formed nanoparticles were examined by 
TEM and SEM (Figure 2). It can be seen that all of the na- 
 
Figure 1  A, Schematic diagram of the preparation of the nanoparticles. B, 
Hydrodynamic diameter distribution of the genipin cross-linked PL-   
heparin nanoparticles determined by DLS. 
 
Figure 2  TEM (A) and SEM (B) image of the genipin cross-linked 
PL-heparin nanoparticles. 
noparticles exhibited a spherical shape with a narrowly dis-
tributed diameter of 230 nm, which is smaller than the hy-
drodynamic diameter determined by DLS due to the dry 
state in the TEM observation. 
To confirm the chemical structure of the particles, Fouri-
er transform infrared (FTIR) spectroscopic analysis of PL, 
heparin and PL-heparin nanoparticles was performed. Fig-
ure 3 shows the FTIR spectra of PL, heparin, genipin 
cross-linked PL-heparin nanoparticles. In the spectrum of 
PL, the characteristic peak at 1673 cm1 corresponds to the 
carbonyl stretching of secondary amide (amide I band) and 
a peak at 1560 cm1 is attributed to the N-H bending vibra-
tions. The peaks located at 3402 and 1620 cm1 could be 
assigned to the hydroxyl stretching vibration and the car-
bonyl stretching vibration, respectively. The spectrum of the 
PL-heparin nanoparticles had characteristic peaks similar to 
the parent molecules. However, some minor changes in the  
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Figure 3  FTIR spectra of PL, heparin, and PL-heparin nanoparticles.  
spectrum were observed, for example, the absorption band 
at 1673 and 1620 cm1 became wider in the nanoparticles. 
These data indicated significant ionic interaction between 
the PL and heparin molecules.  
2.3  In vitro release from nanoparticles  
Considering that the heparin could bind a multitude of 
growth factors and maintain their bioactivity for an extend-
ed period of time [30], the PL-heparin nanoparticles seem to 
be very appropriate to be the carriers for growth factor de-
livery. To evaluate the potential of PL-heparin nanoparticles 
as a drug delivery system, the growth factors were loaded 
into the nanoparticles. Consequently, we successfully en-
capsulated the NGF and bFGF into the nanoparticles by 
their specific binding with heparin. PL solution containing 
growth factors was added to heparin solution to prepare the 
particles, and then the particles were cross-linked with gen-
ipin. A satisfactory encapsulation efficiency of NGF and 
bFGF was found to be about 98.1% and 99.3%, respectively. 
The size distribution of growth factor loaded particles did 
not significantly change compared with that of the unloaded 
nanoparticles (data not shown), since the ratio of growth 
factor in the particles is small. 
 
 
Figure 4  In vitro release profiles of NGF (A) and bFGF (B) released 
from nanoparticles. 
The in vitro release of growth factors from nanoparticles 
was examined. Figure 4 shows the cumulative in vitro re-
lease profiles up to 20 days of growth factors from the par-
ticles in release medium at 37°C. A sustained and no initial 
burst in vitro release profile of growth factors (NGF and 
bFGF) from the particles was observed, which may be as-
cribed to the strong binding between particles and growth 
factors. Since heparin has specific affinity with many 
growth factors, such as NGF and bFGF, the mechanism for 
growth factor release from particles is quite different from 
that of physically or electrostatically encapsulating growth 
factors which usually have much larger initial burst from 
the nanoparticles [31]. For the bFGF, ~42.5% of the loaded 
growth factor was released from particles within 20 days. 
However, ~59.4% of the loaded growth factor was released 
from particles within 20 days for the NGF. This phenome-
non can be attributed to the different binding constants be-
tween heparin and growth factors (bFGF has the high affin-
ity binding with proteoglycan heparin via specific electro-
static interaction. However, NGF has the low affinity with 
proteoglycan heparin) [32,33]. This result suggests that 
growth factors loaded nanoparticles show a continuous and 
slow release behavior for NGF and bFGF. 
2.4  In vitro cytotoxicity of nanoparticles  
To examine the cytotoxicity of the growth factors loaded 
nanoparticles, the in vitro cytotoxicity tests against the 
RSC-96 cells were conducted. The RSC-96 cells were cul-
tivated in the DMEM culture medium with various concen-
trations of nanoparticles for 24 h (Figure 5). It is found that 
the viability of RSC-96 cells cultured in the nanoparticle 
solution was not significantly different from that in DMEM 
supplemented with 10% fetal calf serum (blank control), 
which indicated that the nanoparticles have no obvious cy-
totoxic effect at all used conditions. However, the viability 
of cells cultured with the medium containing growth factors 
loaded nanoparticles is higher than that of the nanoparticle 
group, since the growth factor may promote the survival and 
proliferation of schwann cells. Furthermore, the cells that 
were observed with optical microscopy after 12 h in culture 
in the solution were still active. Bright-field images show 
that all cells proliferate very well and maintain their normal 
configuration at all used conditions (data not shown). 
2.5  In vitro bioactivity of nanoparticles  
To examine whether the released growth factors is still bio-
logically active, the in vitro bioactivity tests of growth fac-
tors against PC12 cells were conducted. PC12 cells origi-
nated from pheochromocytoma of a rat adrenal medulla, 
sprout neuritis and differentiate into sympathetic gangli-
on-like cell in response to growth factors. Therefore, this 
model is usually used to evaluate the neuronal differentia-
tion. 
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Figure 5  In vitro cytotoxicity of PL-heparin nanoparticles and growth 
factors loaded nanoparticles against RSC-96 cells. 
 
Figure 6  The percentage of neurite-bearing PC12 cells in whole popula-
tion treated with various samples after seven days culture.  
The neurite outgrowth of PC12 cells was investigated by 
counting the number of neurite-bearing PC12 cells (Figure 
6). After seven days culture, the percentage of neurite- 
bearing (differentiated) cells treated with blank nanoparti-
cles or DMEM medium is small. When cells were treated 
with growth factor, the percentage of neurite-bearing cells 
increased dramatically. Interestingly, the percentage of neu-
rite-bearing cells treated with combination of bFGF and 
NGF has the highest ratio in all used groups. The synergis-
tic effect of the combined growth factors enables the higher 
neurite-bearing percentage. Meanwhile, the cells treated 
with the growth factor loaded nanoparticles exhibited simi-
lar results. However, the nanoparticle group showed a little 
lower percentage than free growth factors at equal concen-
tration after seven days culture at the tested concentration. 
This phenomenon can be attributed to the sustained release 
property of growth factors loaded nanoparticles.  
To confirm the differentiation from PC12 cells to the 
neuronal cell phenotype, the cultured cells were fixed and 
immunostained with two neuronal markers, β-tubulin III 
and NF200 (Figure 7). It is shown that PC12 cells treated 
with blank nanoparticles and control group have not differ-
entiated to sympathetic ganglion-like cells. In contrast, sig-
nificant differentiation appears when PC12 cells were 
treated with growth factor or growth factor loaded nanopar-
ticles. The neurite length of PC12 cells treated with combi-
nation of NGF and bFGF was longer than that of cells 
treated with single growth factor. The neurite length of 
PC12 cells treated with NGF is longer than that treated with 
bFGF [34]. Additionally, the nanoparticle groups displayed 
the similar trends concerning the percentage of neu-
rite-bearing cells treated with nanoparticles. The immuno- 
cytochemical analysis indicated that combination of NGF 
and bFGF has synergistic effect on the differentiation of 
PC12 cells.  
 
 
Figure 7  Immunocytochemical fluorescence images of differentiated 
PC12 cells 7 days after treated with various samples. For each panel, the 
images from left to right show β-tubulin III fluorescence in cells (green), 
NF-200 fluorescence in cells (red), cell nuclei stained by DAPI (blue), and 
overlays of the above images. Scale bar, 100 μm. 
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3  Conclusion 
The novel polymeric nanoparticle delivery system com-
posed of heparin and PL was prepared for controlled release 
of NGF and bFGF. The nanoparticles were fabricated by 
polyelectrolyte complexation method, followed by cross- 
linking with biological genipin. NGF and bFGF were en-
capsulated in the nanoparticles and show a continuous and 
slow release behavior in vitro. The bioactivity of the re-
leased growth factors was evaluated, and exhibited the syn-
ergistic effect. The controlled release of the dual synergistic 
growth factors would improve the treatment of peripheral 
nerve injury to mimic the natural cellular microenviron-
ments. 
This work was supported by the National High Technology Research and 
Development Program of China (2012AA020502), National Natural Sci-
ence Foundation of China (81171457, 81371687), Natural Science Foun-
dation of Jiangsu Province of China (BK20130390), Natural Science 
Foundation of Nantong City (BK2012089), the Natural Science Research 
Program of Jiangsu Education Department (13KJB310014), the Priority of 
Academic Program Development of Jiangsu Higher Education Institutions 
and Natural Science Foundation of Nantong University (10Z014). 
1 Konofaos P, Halen JPV. Nerve repair by means of tubulization: past, 
present, future. J Reconstruct Microsurg, 2013, 29: 149–163 
2 Wang XD, Hu W, Cao Y, Yao J, Wu J, Gu XS. Dog sciatic nerve 
regeneration across a 30-mm defect bridged by a chitosan/PGA 
artificial nerve graft. Brain, 2005, 128: 1897–1910 
3 Evans GR. Challenges to nerve regeneration. Semin Surg Oncol, 
2000, 19: 312–318 
4 Huang W, Begum R, Barber T, Ibba V, Tee NC, Hussain M, Arastoo 
M, Yang Q, Robson LG, Lesage S, Gheysens T, Skaer NJ, Knight DP, 
Priestley JV. Regenerative potential of silk conduits in repair of 
peripheral nerve injury in adult rats. Biomaterials, 2012, 33: 59–71 
5 Lee BK, Ju YM, Cho JG, Jackson JD, Lee SJ, Atala A, Yoo JJ. End- 
to-side neurorrhaphy using an electrospun PCL/collagen nerve 
conduit for complex peripheral motor nerve regeneration. 
Biomaterials, 2012, 33: 9027–9036 
6 Khaing ZZ, Schmidt CE. Advances in natural biomaterials for nerve 
tissue repair. Neurosci Lett, 2012, 519: 103–114 
7 Belkas JS, Shoichet MS, Midha R. Axonal guidance channels in 
peripheral nerve regeneration. Oper Tech Orthop, 2004, 14: 190-198 
8 Pabari A, Yang SY, Seifalian AM, Mosahebi A. Modern surgical 
management of peripheral nerve gap. J Plastic Reconstruct Aesthet 
Surg, 2010, 63: 1941–1948 
9 Daly W, Yao L, Zeugolis D, Windebank A, Pandit A. A biomaterials 
approach to peripheral nerve regeneration: bridging the peripheral 
nerve gap and enhancing functional recovery. J Royal Soc Interface, 
2012, 9: 202–221 
10 Ho PR, Coan GM, Cheng ET, Niell C, Tarn DM, Zhou H, Sierra D, 
Terris DJ. Repair with collagen tubules linked with brain-derived 
neurotrophic factor and ciliary neurotrophic factor in a rat sciatic 
nerve injury model. Arch Otolaryngol Head Neck Surg, 1998, 124: 
761–766 
11 Aebischer P, Salessiotis AN, Winn SR. Basic fibroblast growth factor 
released from synthetic guidance channels facilitates peripheral nerve 
regeneration across long nerve gaps. J Neurosci Res, 1989, 23: 
282–289 
12 Gu X, Ding F, Yang Y, Liu J. Construction of tissue engineered 
nerve grafts and their application in peripheral nerve regeneration. 
Prog Neurobiol, 2011, 93: 204–230  
13 Lundborg G. A 25-year perspective of peripheral nerve surgery:  
evolving neuroscientific concepts and clinical significance. J Hand 
Surg Am, 2000, 25: 391–414 
14 Flight MH. Neurotrophic factors: ride back to the nucleus. Nat Rev 
Neurosci, 2011, 12: 550–551 
15 Davis JB, Stroobant P. Platelet-derived growth factors and fibroblast 
growth factors are mitogens for rat Schwann cells. J Cell Biol, 1990, 
110: 1353–1360 
16 Torigoe K, Hashimoto K, Lundborg G. A role of migratory Schwann 
cells in a conditioning effect of peripheral nerve regeneration. Exp 
Neurol, 1999, 160: 99–108 
17 Madduri S, Gander B. Growth factor delivery systems and repair 
strategies for damaged peripheral nerves. J Contr Release, 2012, 161: 
274–282 
18 Madduri S, Papaloizos M, Gander B. Synergistic effect of GDNF and 
NGF on axonal branching and elongation in vitro. Neurosci Res, 
2009, 65: 88–97 
19 Zeng W, Huang J, Xiao W, Rong M, Yuan Z, Luo Z. Ionically 
cross-linked chitosan microspheres for controlled release of bioactive 
nerve growth factor. Int J Pharm, 2011, 421: 283–290 
20 Dyondi D, Webster TJ, Banerjee R. A nanoparticulate injectable 
hydrogel as a tissue engineering scaffold for multiple growth factor 
for multiple growth factor delivery for bone regeneration. Int J 
Nanomed, 2013, 8: 47–59 
21 Zhang Y, Chan HF, Leong KW. Advanced materials and processing 
for drug delivery: the past and the future. Adv Drug Deliv Rev, 2013, 
65: 104–120 
22 Liu JM, Wang X, Marin-Muller C, Wang H, Lin PH, Yao Q, Chen C. 
Current advances in research and clinical application of PLGA-based 
nanotechnology. Expert Rev Mol Diagn, 2009, 9: 325–341  
23 Shukla SC, Singh A, Pandey AK, Mishra A. Review on production 
and medical applications of epsilon-polylysine. Biochem Eng J, 2012, 
65: 70–81 
24 Lin YH, Chang CH, Wu YS, Hsu YM, Chiou SF, Chen YJ. 
Development of pH-responsive chitosan/heparin nanoparticles for 
stomach-specific anti-Helicobacter pylori therapy. Biomaterials, 2009, 
30: 3332–3342 
25 Chu HH, Johnson NR, Mason NS, Wang YD. A [polycation:heparin] 
complex releases growth factors with enhanced bioactivity. J Contr 
Release, 2011, 150: 157–163 
26 Goncalves NP, Oliveira H, Pego AP, Saraiva MJ. A novel 
nanoparticle delivery system for in vivo targeting of the sciatic nerve: 
impact on regeneration. Nanomedicine, 2012, 7: 1167–1180 
27 Chau CH, Shum DK, Chan YS, So KF. Heparan sulphates upregulate 
regeneration of transected sciatic nerves of adult guinea-pigs. Eur J 
Neurosci, 1999, 11: 1914–1926 
28 Yang YM, Zhao WJ, He JH, Zhao YH, Ding F, Gu XS. Nerve 
conduits based on immobilization of nerve growth factor onto 
modified chitosan by using genipin as a crosslinking agent. Eur J 
Pharm Biopharm, 2011, 79: 519–525 
29 Mi FL, Tan YC, Liang HF, Sung HW. In vivo biocompatibility and 
degradability of a novel injectable-chitosan-based implant. 
Biomaterials, 2002, 23: 181–191 
30 Zern BJ, Chu HH, Wang YD. Control growth factor release using a 
self-assembled [polycation:heparin] complex. PLoS ONE, 2010, 5: 
e11017 
31 Stanwick JC, Baumann MD, Schoichet MS. Enhanced neurotrophin- 
3 bioactivity and release from a nanoparticle-loaded composite 
hydrogel. J Contr Release, 2012, 160: 666–675 
32 Sakiyama-Elbert SE, Hubbell JA. Controlled release of nerve growth 
factor from a heparin-containing fibrin-based cell ingrowth matrix. J 
Contr Release, 2000, 69: 149–158 
33 Freeman I, Kedem A, Cohen S. The effect of sulfation of alginate 
hydrogels on the specific binding and controlled release of 
heparin-binding proteins. Biomaterials, 2008, 29: 3260–3268 
34 Chung J, Kubota H, Ozaki Y, Uda S, Kuroda S. Timing-dependent 
actions of NGF required for cell differentitation. PLoS ONE, 2010, 5: 
e9011
 
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction 
in any medium, provided the original author(s) and source are credited. 
